跳至主要内容
临床试验/NCT05237661
NCT05237661已完成不适用

Study to Evaluate the Efficacy of Your Super's Moon Balance and Its Impact on Premenstrual Syndrome and Menstrual Symptoms

Your Super, INC.2 个研究点 分布在 1 个国家目标入组 38 人开始时间: 2022年2月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
38
试验地点
2
主要终点
Change in perceived discomfort associated with menstruation

研究概览

简要总结

This is an open-label observational single-group clinical trial to study the efficacy of a commercially available dietary supplement and its effect on common PMS and menstrual symptoms, as well as health-related biomarkers.

详细描述

It is hypothesized that the dietary supplement marketed as "YOUR SUPER Moon Balance" will improve subjective wellbeing in trial participants by alleviating common symptoms of PMS and menstrual symptoms, such as pain, cramps, bloating, and lack of energy. Further, the ability of the supplement to reduce biomarkers of inflammation (CRP) and stress (cortisol), and promote sleep, will be evaluated.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Individuals with a regular menstruation
  • Age 18-40
  • Moderate self-reported discomfort during menstruation-related to bloating, cramps, fatigue, mood swings, or other PMS-related symptoms
  • Must be in generally good health - no unstable, uncontrolled health condition
  • BMI under 35
  • Self-reported sleep-issues
  • Willingness to refrain from ibuprofen or naproxen sodium (such as Advil, Aleve, Motrin or Midol) during each period (pill bleed) during the study
  • Agree to not change their diet significantly during the duration of the study
  • Agree to not change the intensity of their workouts for the duration of the study
  • Must get their period regularly

排除标准

  • Severe chronic conditions, including oncological and psychiatric disorders
  • Known to have any severe allergic reactions
  • Currently pregnant, breastfeeding, or wanting to become pregnant for the duration of the study
  • Participants unwilling to follow the study protocol
  • Have used a similar product (ingredients) in the 6 weeks prior to the study

结局指标

主要结局

Change in perceived discomfort associated with menstruation

时间窗: 12 weeks

Perceived discomfort caused by several of the most common menstrual symptoms (energy, sleep, mood, comfort, and overall fewer PMS symptoms) Each endpoint will be reported by the participant on a scale of perceived discomfort at the end of each menstrual cycle. Participants will complete the surveys for each menstrual cycle. The study uses a questionnaire including a scale from 0-7 to assess the severity of symptoms(0=no symptoms and 7=very severe symptoms).

次要结局

  • Changes in saliva cortisol levels(12 weeks)
  • Change in blood biomarkers: C-reactive protein(12 weeks)

研究者

发起方
Your Super, INC.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

已完成
不适用
Study to Evaluate the Efficacy of YOUR SUPER Detox Bundle to Improve Perceived Well Being and Promote Adaptation of Healthy Dietary ChoicesEating HabitHealthy Diet
NCT05303207Your Super, INC.38
已完成
不适用
Study to Evaluate the Efficacy of Asystems' Complete Calm Supplementation on Sleep Quality and Duration, Anxiety, and StressSleepStressAnxiety
NCT05190640Asystem, Inc.35
已完成
不适用
An Open-Label Clinical Study to Evaluate the Efficacy of a Face Cream and Eye CreamWrinkleFine LinesPhotoaging
NCT04911374Revision Skincare45
招募中
2 期
Effectiveness and safety of LM011 in treating subjects diagnosed with non-alcoholic steatohepatitis (NASH).on-Alcoholic Steatohepatitis (NASH)Non-Alcoholic Steatohepatitis (NASH)Metabolic and Endocrine - Metabolic disordersOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
ACTRN12619000610134ifemax Laboratories (Australia) Pty Ltd20
进行中(未招募)
1 期
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 18.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 18.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 18.1Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 18.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2015-005597-38-ESRoche Farma S.A. que representa en España a F. Hoffmann-La Roche Ltd600